BioRestorative Therapies Aktie

BioRestorative Therapies für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A3C9XF / ISIN: US0906556065

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
23.04.2025 15:55:11

EQS-News: Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies

EQS-News: Benzinga / Key word(s): Healthcare
Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies

23.04.2025 / 15:55 CET/CEST
The issuer is solely responsible for the content of this announcement.


By Meg Flippin Benzinga

DETROIT, MICHIGAN - April 23, 2025 (NEWMEDIAWIRE) - Lance Alstodt, CEO of BioRestorative Therapies (NASDAQ: BRTX), was recently a guest on Benzinga’s All-Access. 

6808e3e6da846f54e5160f30_1

BioRestorative Therapies is a regenerative medicine company that wants to alleviate chronic lower back pain, obesity and diabetes and is developing stem cell therapies to meet that end. The company’s flagship program, BRTX-100, which is in a phase 2 clinical trial, uses a patient’s stem cells to alleviate chronic back pain. Meanwhile, ThermoStem®  uses adipose-derived (brown fat) stem cells to generate new brown fat tissue to target metabolic diseases, including obesity and type 2 diabetes. Both are addressing unmet health needs that inflict pain and suffering on millions of people around the world. 

Watch the full interview here: 
https://www.youtube.com/watch?v=JkHcW6QMRlg

Featured image by Joyce Hankins on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

This content was originally published on Benzinga. Read further disclosures here.


News Source: Benzinga


23.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Benzinga
United States
ISIN: US0906556065
EQS News ID: 2122726

 
End of News EQS News Service

2122726  23.04.2025 CET/CEST

Analysen zu BioRestorative Therapies Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel